Platform
T-CAMP : Next-Generation T-Cell Therapy Manufacturing Platform
First-in-world implementation of in vivo mechanical force
Ex vivo expansion of T-Cell
MC-EXP
Rapid generation of highly functional T cells by
mimicking in vivo physical signals
T-CAST
Automated culture optimization through
deep-learning-based image analysis
Cost Advantage
Ex vivo T-cell expansion at only
1/10 the cost of conventional methods
Vision
“Toward the Global Standardization of
T-Cell Therapy Manufacturing”
R&D : Redefining TCR-T Therapies with Monomeric TCRs
Overcoming immune checkpoints through IST GO mRNA-based novel TCR expression
Patient-derived neoantigen-specific TCR archive established
Cell Theraphy Process
01
Blood Collection
Only about 40ml of the patient’s blood is collected, and immune cells (PBMCs) are isolated for preparation.
02
Rapid Expansion with
Enhanced Functionality
By mimicking in vivo environment, T cells are rapidly expanded within 7 days, with enhanced stemness and bio-persistency.
03
Safe Patient-Tailored
TCR Expression
Safe TCR expression via mRNA delivery using patient-derived monomeric TCR libraries.
04
Patient-Friendly Therapy
Achieves therapeutic effect with only one-third of the conventional dose. Based on the patient’s own (autologous) cells, making the therapy safe, simple, and cost-effective.